Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Insmed, Inc. (INSM : NSDQ)
 
 • Company Description   
Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

Number of Employees: 613

 
 • Price / Volume Information   
Yesterday's Closing Price: $18.19 Daily Weekly Monthly
20 Day Moving Average: 1,328,573 shares
Shares Outstanding: 119.52 (millions)
Market Capitalization: $2,174.02 (millions)
Beta: 2.06
52 Week High: $34.44
52 Week Low: $16.41
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -29.08% -22.59%
12 Week -20.08% -13.62%
Year To Date -33.22% -20.91%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
700 US Highway 202/206
-
Bridgewater,NJ 08807
USA
ph: 908-977-9900
fax: 732-438-0381
investor.relations@insmed.com http://www.insmed.com
 
 • General Corporate Information   
Officers
William H. Lewis - Chair and Chief Executive Officer
Sara Bonstein - Chief Financial Officer
David R. Brennan - Director
Elizabeth McKee Anderson - Director
David W.J. McGirr - Director

Peer Information
Insmed, Inc. (CORR.)
Insmed, Inc. (RSPI)
Insmed, Inc. (CGXP)
Insmed, Inc. (BGEN)
Insmed, Inc. (GTBP)
Insmed, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 457669307
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 119.52
Most Recent Split Date: 3.00 (0.10:1)
Beta: 2.06
Market Capitalization: $2,174.02 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.90 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.56 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 18.05
Price/Cash Flow: -
Price / Sales: 10.80
EPS Growth
vs. Year Ago Period: 10.11%
vs. Previous Quarter: 15.79%
Sales Growth
vs. Year Ago Period: 32.06%
vs. Previous Quarter: -5.38%
ROE
03/31/22 - -108.20
12/31/21 - -102.11
09/30/21 - -108.34
ROA
03/31/22 - -34.32
12/31/21 - -37.58
09/30/21 - -40.69
Current Ratio
03/31/22 - 6.04
12/31/21 - 6.19
09/30/21 - 8.52
Quick Ratio
03/31/22 - 5.52
12/31/21 - 5.70
09/30/21 - 7.92
Operating Margin
03/31/22 - -210.41
12/31/21 - -223.22
09/30/21 - -235.92
Net Margin
03/31/22 - -217.35
12/31/21 - -230.63
09/30/21 - -243.96
Pre-Tax Margin
03/31/22 - -218.15
12/31/21 - -231.57
09/30/21 - -230.16
Book Value
03/31/22 - 1.01
12/31/21 - 3.47
09/30/21 - 4.26
Inventory Turnover
03/31/22 - 0.72
12/31/21 - 0.72
09/30/21 - 0.70
Debt-to-Equity
03/31/22 - 6.73
12/31/21 - 1.41
09/30/21 - 1.13
Debt-to-Capital
03/31/22 - 87.06
12/31/21 - 58.59
09/30/21 - 53.09
 

Powered by Zacks Investment Research ©